Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 26.84M | 45.23M | 54.22M | 94.59M | 56.34M |
Gross Profit | 14.91M | 25.16M | 34.83M | 71.31M | 37.57M |
EBITDA | -27.22M | -15.79M | -27.10M | -2.89M | -102.72M |
Net Income | -34.24M | -15.48M | -38.45M | -22.12M | -110.03M |
Balance Sheet | |||||
Total Assets | 260.93M | 302.95M | 333.55M | 376.40M | 381.30M |
Cash, Cash Equivalents and Short-Term Investments | 27.05M | 26.73M | 31.60M | 77.89M | 71.08M |
Total Debt | 40.93M | 45.91M | 51.13M | 59.66M | 55.06M |
Total Liabilities | 84.98M | 87.77M | 91.52M | 92.35M | 83.91M |
Stockholders Equity | 194.68M | 230.26M | 224.30M | 256.25M | 267.53M |
Cash Flow | |||||
Free Cash Flow | 10.67M | 4.51M | -31.71M | 14.86M | 49.20M |
Operating Cash Flow | 10.69M | 5.10M | -30.36M | 16.32M | 49.54M |
Investing Cash Flow | -3.00K | 364.00K | -1.23M | -1.42M | -11.22M |
Financing Cash Flow | -10.85M | -8.77M | -12.49M | -7.22M | -2.54M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% | |
49 Neutral | HK$315.19M | ― | -16.11% | ― | -40.65% | -121.13% | |
46 Neutral | HK$312.08M | ― | -4.04% | ― | 12.86% | -297.41% | |
44 Neutral | HK$334.38M | ― | -18.37% | ― | -2.69% | -53.59% | |
44 Neutral | HK$198.68M | ― | -31.95% | ― | -70.49% | -129.16% | |
43 Neutral | HK$207.20M | ― | -17.37% | ― | -3.54% | -49.42% | |
35 Underperform | €539.27M | ― | -36.48% | ― | 1.87% | -42.24% |
China Tian Yuan Healthcare Group Limited announced capital injections and a shareholder loan involving its subsidiaries, Hengqin Hanyuemei and Shanghai Rifu, and a third party, Shanghai Huaman. The capital injections will increase Shanghai Rifu’s registered capital significantly, while the shareholder loan will provide additional financial support. These transactions, which are part of a series of agreements with Shanghai Huaman, are subject to disclosure requirements under Hong Kong’s listing rules due to their size.
China Tian Yuan Healthcare Group Limited announced that all resolutions proposed at their Annual General Meeting on June 27, 2025, were unanimously approved by shareholders. These resolutions included the re-election of directors, authorization of directors’ remuneration, reappointment of auditors, and granting of general mandates for issuing and repurchasing shares, indicating strong shareholder support and stability in the company’s governance and operational strategies.
China Tian Yuan Healthcare Group Limited has announced its thirty-sixth annual general meeting to be held on June 27, 2025, in Hong Kong. Key agenda items include the re-election of directors, approval of directors’ remuneration, and the re-appointment of auditors. Additionally, the company seeks approval to allot and issue additional shares, which could impact its capital structure and shareholder value.